The European Medicines Agency (EMA), which is the regulator for vaccines and medicine in the European Union (EU), has stopped ...

As users continue to leave X (formerly Twitter) en masse, many in favor of the newer Bluesky platform, the European Medicines ...

X4 Pharmaceuticals (XFOR) announced that its Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome, a rare ...

Doctors say new research has found a link between weight-loss drugs and cancer, putting users at 'significantly higher risk' ...

An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower ...

Submission supported by positive results from global, Phase 3 4WHIM clinical trial; U.S. regulatory approval in WHIM syndrome ...

Investing.com -- Shares of Ionis Pharmaceuticals (NASDAQ: IONS) climbed 7% today after the company announced that regulatory agencies in the United States and Europe have accepted applications for a ...

Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.

American doctors have now discovered the injections put users at 'significantly higher' risk compared to three other common diabetes drugs.

San Francisco, California Friday, January 24, 2025, 11:00 Hrs [IST] ...

CHICAGO - Cosmos Health Inc. (NASDAQ:COSM), a global healthcare group, announced Monday that it has broadened its exclusive ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled ...